Amid US Challenges, Will Glenmark’s R&D Pipeline Deliver?

Glenmark reported subdued Q2 earnings, with the management predicting that the US business environment could stay challenging for at least two years. The firm, though, was upbeat on the potential of certain R&D assets, with a monoclonal antibody seen as “most promising” from an out-licensing perspective and a combination for seasonal allergic rhinitis set for a US NDA filing early next year.